Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients

Cancer Medicine

Volumn 5, Issue 1, 2016, Pages 41-48

  Iwase, Toshiaki ^a   Sangai, Takafumi ^a   Nagashima, Takeshi ^a   Sakakibara, Masahiro ^a   Sakakibara, Junta ^a   Hayama, Shouko ^a   Ishigami, Emi ^a   Masuda, Takahito ^a   Miyazaki, Masaru ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Body composition; Breast neoplasms; Menopause; Neoadjuvant therapy; Survival

Indexed keywords

ANTHRACYCLINE DERIVATIVE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ABDOMINAL CIRCUMFERENCE; ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY FAT DISTRIBUTION; BODY MASS; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HEMATOLOGIC DISEASE; HER2 NEGATIVE BREAST CANCER; HER2 POSITIVE BREAST CANCER; HUMAN; HUMAN TISSUE; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; NEUTROPENIA; OBESITY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKELETAL MUSCLE; SUBCUTANEOUS FAT; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; UNDERWEIGHT; UNSPECIFIED SIDE EFFECT; BREAST NEOPLASMS; CANCER STAGING; COMPLICATION; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; RISK FACTOR; SURVIVAL ANALYSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY FAT DISTRIBUTION; BODY MASS INDEX; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OBESITY; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85006213887     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.571     Document Type: Article

References (32)

1. Litton, J. K., A. M. Gonzalez-Angulo, C. L. Warneke, A. U. Buzdar, S. W. Kau, M. Bondy, et al. 2008. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J. Clin. Oncol. 26:4072-4077.
2. Renehan, A. G., M. Tyson, M. Egger, R. F. Heller, and M. Zwahlen . 2008. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569-578.
3. Iwase, T., R. Nakamura, N. Yamamoto, A. Yoshi, M. Itami, and M. Miyazaki . 2014. The effect of molecular subtype and body mass index on neo-adjuvant chemotherapy in breast cancer patients. Breast 23:264-272.
4. Palmer, B. F., and D. J. Clegg . 2015. The sexual dimorphism of obesity. Mol. Cell. Endocrinol. 402C:113-119.
5. Vernon, G., A. Baranova, and Z. M. Younossi . 2011. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34:274-285.
6. van Kruijsdijk, R. C., E. van der Wall, and F. L. Visseren . 2009. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol. Biomarkers Prev. 18:2569-2578.
7. Donohoe, C. L., S. L. Doyle, S. McGarrigle, M. C. Cathcart, E. Daly, A. O'Grady, et al. 2012. Role of the insulin-like growth factor 1 axis and visceral adiposity in oesophageal adenocarcinoma. Br. J. Surg. 99:387-396.
8. Del Fabbro, E., H. Parsons, C. L. Warneke, K. Pulivarthi, J. K. Litton, R. Dev, et al. 2012. The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist 17:1240-1245.
9. Wu, W., X. Liu, P. Chaftari, M. T. Cruz Carreras, C. Gonzalez, J. Viets-Upchurch, et al. 2015. Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective review. PLoS ONE 10:e0122047.
10. Edge, S. B. B. D., C. C. Compton, A. G. Fritz, F. L. Greene, and A. Trotti . 2009. American joint committee on cancer staging manual, 7th ed. Spinger, New York, NY.
11. Mitsiopoulos, N., R. N. Baumgartner, S. B. Heymsfield, W. Lyons, D. Gallagher, and R. Ross . 1998. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J. Appl. Physiol. (1985) 85:115-122.
12. Prado, C. M., J. R. Lieffers, L. J. McCargar, T. Reiman, M. B. Sawyer, L. Martin, et al. 2008. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 9:629-635.
13. Ricci, C., R. Longo, E. Gioulis, M. Bosco, P. Pollesello, F. Masutti, et al. 1997. Noninvasive in vivo quantitative assessment of fat content in human liver. J. Hepatol. 27:108-113.
14. Rastogi, P., S. J. Anderson, H. D. Bear, C. E. Geyer, M. S. Kahlenberg, A. Robidoux, et al. 2008. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J. Clin. Oncol. 26:778-785.
15. Untch, M., M. Rezai, S. Loibl, P. A. Fasching, J. Huober, H. Tesch, et al. 2010. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J. Clin. Oncol. 28:2024-2031.
16. Buzdar, A. U., N. K. Ibrahim, D. Francis, D. J. Booser, E. S. Thomas, R. L. Theriault, et al. 2005. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J. Clin. Oncol. 23:3676-3685.
17. von Minckwitz, G., M. Untch, J. U. Blohmer, S. D. Costa, H. Eidtmann, P. A. Fasching, et al. 2012. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol. 30:1796-1804.
18. Fisher, B., J. Bryant, N. Wolmark, E. Mamounas, A. Brown, E. R. Fisher, et al. 1998. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16:2672-2685.
19. Green, M. C., A. U. Buzdar, T. Smith, N. K. Ibrahim, V. Valero, M. F. Rosales, et al. 2005. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J. Clin. Oncol. 23:5983-5992.
20. Examination Committee of Criteria for 'Obesity Disease' in J, Japan Society for the Study of O. 2002. New criteria for 'obesity disease, Japan. Circ. J. 66:987-992.
21. Baumgartner, R. N., K. M. Koehler, D. Gallagher, L. Romero, S. B. Heymsfield, R. R. Ross, et al. 1998. Epidemiology of sarcopenia among the elderly in New Mexico. Am. J. Epidemiol. 147:755-763.
22. Carey, L. A., C. M. Perou, C. A. Livasy, L. G. Dressler, D. Cowan, K. Conway, et al. 2006. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502.
23. Voduc, K. D., M. C. Cheang, S. Tyldesley, K. Gelmon, T. O. Nielsen, and H. Kennecke . 2010. Breast cancer subtypes and the risk of local and regional relapse. J. Clin. Oncol. 28:1684-1691.
24. Wong, A. L., K. Y. Seng, E. M. Ong, L. Z. Wang, H. Oscar, M. T. Cordero, et al. 2014. Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. Breast Cancer Res. Treat. 144:143-152.
25. Barbat-Artigas, S., and M. Aubertin-Leheudre . 2013. Menopausal transition and fat distribution. Menopause 20:370-371.
26. Messier, V., R. Rabasa-Lhoret, S. Barbat-Artigas, B. Elisha, A. D. Karelis, and M. Aubertin-Leheudre . 2011. Menopause and sarcopenia: a potential role for sex hormones. Maturitas 68:331-336.
27. Prado, C. M., V. E. Baracos, L. J. McCargar, T. Reiman, M. Mourtzakis, K. Tonkin, et al. 2009. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin. Cancer Res. 15:2920-2926.
28. Martin, L., L. Birdsell, N. Macdonald, T. Reiman, M. T. Clandinin, L. J. McCargar, et al. 2013. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 31:1539-1547.
29. Fontanella, C., B. Lederer, S. Gade, M. Vanoppen, J. U. Blohmer, S. D. Costa, et al. 2015. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res. Treat. 150:127-139.
30. Arce-Salinas, C., J. L. Aguilar-Ponce, C. Villarreal-Garza, F. U. Lara-Medina, D. Olvera-Caraza, A. Alvarado Miranda, et al. 2014. Overweight and obesity as poor prognostic factors in locally advanced breast cancer patients. Breast Cancer Res. Treat. 146:183-188.
31. Despres, J. P., and I. Lemieux . 2006. Abdominal obesity and metabolic syndrome. Nature 444:881-887.
32. Irwin, M. L. 2014. Weight loss interventions and breast cancer survival: the time is now. J. Clin. Oncol. 32:2197-2199.